<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2165">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05132972</url>
  </required_header>
  <id_info>
    <org_study_id>BRIN20211118a</org_study_id>
    <nct_id>NCT05132972</nct_id>
  </id_info>
  <brief_title>Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients</brief_title>
  <acronym>UCMSC</acronym>
  <official_title>Efficacy and Safety of Normoxic Allogenic Umbilical Cord Mesenchymal Stem Cells Administered as Adjuntive Treatment to Standard Treatment in Severe Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Moewardi General Hospital, Surakarta, Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Sardjito General Hospital, Yogyakarta, Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Hasan Sadikin General Hospital, Bandung, Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PT Bifarma Adiluhung</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to assess the efficacy and safety of stem cells as adjunctive&#xD;
      treatment for severe COVID-19 patients. Here, we want to study whether the administration of&#xD;
      mesenchymal stem cells are safe and able to relieve some of the COVID-19 symptoms&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled trial. double-blind, multi-center clinical study conducted at&#xD;
      three different hospitals, on 21 patients who received intervention and 21 patients who&#xD;
      received control treatment. The purpose of this study is to evaluate the efficacy and safety&#xD;
      of intravenous administration of normoxic allogeneic umbilical cord-derived mesenchymal stem&#xD;
      cell (UCMSC) in the treatment group, compared to the control group who are only given&#xD;
      standard COVID-19 treatments and normal saline infusion&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>20 - 24 days</time_frame>
    <description>Number of days since patient was administered until discharge in hospitals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-administration clinical and radiological improvement</measure>
    <time_frame>Baseline/day-1 (-2 days), day-15 (+/- 2 days), day-22 (+/1 2 days) post randomization day</time_frame>
    <description>Chest X-ray evaluation; mMRC(Modified Medical Research Council) Dyspnea scale;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event and Serious Adverse Event Evaluation</measure>
    <time_frame>20 - 24 days</time_frame>
    <description>Evaluation of all adverse event or serious adverse event that is observed or reported by</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Covid 19</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group receiving standard COVID-19 treatment and UCMSC infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Group receiving standard COVID-19 treatment and normal saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Normoxic Allogenic UCMSC</intervention_name>
    <description>Allogenic umbilical cord-derived mesenchymal stem cell (UCMSC) from normoxic, culture condition, administered through intravenousinfusion at dose 1x10^6 cells MSC/kg body weight. The treatment will be administered three times, at three days intervals (day 0, day 3, and day 6)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline solution</intervention_name>
    <description>Sterile saline solution and adminastered through intravenous infusion three times, at three day intervals (day 0, day 3, and day 6)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman age 18-75 years&#xD;
&#xD;
          -  SARS-CoV2 positive as confirmed by SARS-CoV2 RT-PCR Test&#xD;
&#xD;
          -  Diagnosed with pnumonia as confirmed by chect radiography and history of fever, coug&#xD;
             with one of the following symptoms: RR &gt; 30x per minute, SaO2 93%, FaO2/FiO2 300 mmHg&#xD;
&#xD;
          -  Voluntarily joined the clinical trial and has signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and lactating woman&#xD;
&#xD;
          -  Patient who are diagnosed or have history of tumor and cancer&#xD;
&#xD;
          -  Patient whose mother or sister are diagnosed with breast or ovarian cancer&#xD;
&#xD;
          -  Level of SGPT/ALT is â‰¥ 5 times upper limit from normal value&#xD;
&#xD;
          -  Level of eGFR is &lt; 30 ml/min&#xD;
&#xD;
          -  Reluctant to sign informed consent and unwilling to take the required tests&#xD;
&#xD;
          -  Require invasive ventilation&#xD;
&#xD;
          -  Shock&#xD;
&#xD;
          -  Organ failure&#xD;
&#xD;
          -  Currently involve in other clinical trial, or join another clinical trial in the last&#xD;
             3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arief Nurudin, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Moewardi General Hospital, Surakarta, Indonesia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samekto Wibowo, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Sardjito General Hospital, Yogyakarta, Indonesia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmad Faried, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Hasan Sadikin General Hospital, Bandung, Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bintang Soetjahjo, MD PhD</last_name>
    <phone>+628122987359</phone>
    <email>bjortho@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. Moewardi General Hospital</name>
      <address>
        <city>Surakarta</city>
        <state>Central Java</state>
        <zip>57126</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arief Nurudhin, MD, PhD</last_name>
      <phone>+6281393955596</phone>
    </contact>
    <investigator>
      <last_name>Arief Nurudhin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bintang Soetjahjo, MD. PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Purwoko Purwoko, MD. PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Artrian Adhiputri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rina Sidharta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Widiastuti Widiastuti, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Hasan Sadikin</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <zip>40161</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmad Faried, Prof. MD</last_name>
      <phone>+6281320230371</phone>
    </contact>
    <investigator>
      <last_name>Ahmad Faried, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rudi Wisaksana, MD. PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arto Yuwono, MD. PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tri Wahyu Murni, MD. PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reza Sudjud, MD. PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Sardjito General Hospital</name>
      <address>
        <city>Yogyakarta</city>
        <zip>55281</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samekto Wibowo, Prof. MD</last_name>
      <phone>+628122715617</phone>
    </contact>
    <investigator>
      <last_name>Samekto Wibowo, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sumardi Sumardi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sudadi Sudadi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jarir At Thobari, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>E Henry Hamingtyas, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rusdy Ghazali Malueka, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <results_reference>
    <citation>Atluri S, Manchikanti L, Hirsch JA. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. Pain Physician. 2020 Mar;23(2):E71-E83.</citation>
    <PMID>32214286</PMID>
  </results_reference>
  <results_reference>
    <citation>Richardson JB. Urban forests near municipal solid waste incinerators do not show elevated trace metal or rare earth element concentrations across three cities in the northeast USA. Environ Sci Pollut Res Int. 2020 Jun;27(17):21790-21803. doi: 10.1007/s11356-020-08439-3. Epub 2020 Apr 12.</citation>
    <PMID>32281062</PMID>
  </results_reference>
  <results_reference>
    <citation>Liang B, Chen J, Li T, Wu H, Yang W, Li Y, Li J, Yu C, Nie F, Ma Z, Yang M, Xiao M, Nie P, Gao Y, Qian C, Hu M. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Medicine (Baltimore). 2020 Jul 31;99(31):e21429. doi: 10.1097/MD.0000000000021429.</citation>
    <PMID>32756149</PMID>
  </results_reference>
  <results_reference>
    <citation>Galipeau J, SensÃ©bÃ© L. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell. 2018 Jun 1;22(6):824-833. doi: 10.1016/j.stem.2018.05.004. Review.</citation>
    <PMID>29859173</PMID>
  </results_reference>
  <results_reference>
    <citation>Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18. Erratum in: Lancet Respir Med. 2020 Feb 25;:.</citation>
    <PMID>32085846</PMID>
  </results_reference>
  <results_reference>
    <citation>Khoury M, Cuenca J, Cruz FF, Figueroa FE, Rocco PRM, Weiss DJ. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J. 2020 Jun 4;55(6). pii: 2000858. doi: 10.1183/13993003.00858-2020. Print 2020 Jun. Review.</citation>
    <PMID>32265310</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. Moewardi General Hospital, Surakarta, Indonesia</investigator_affiliation>
    <investigator_full_name>Bintang Soetjahjo, SpOT (K), MD. PhD</investigator_full_name>
    <investigator_title>Coordinating Investigator</investigator_title>
  </responsible_party>
  <keyword>COVID19</keyword>
  <keyword>Mesenchymal Stem Cells (MCSs)</keyword>
  <keyword>Adjuvant therapy</keyword>
  <keyword>Indonesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

